Edgewise Therapeutics CFO sells $19k in shares

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Chief Financial Officer, R Michael Carruthers, sold 1,428 shares of common stock on August 12, 2025, at prices ranging from $13.36 to $13.49, realizing approximately $19,124. The transaction comes as the $1.47 billion market cap company has seen its stock surge 7.57% over the past week, though it remains significantly below its 52-week high of $38.12.

According to a Form 4 filing with the Securities and Exchange Commission, Carruthers also exercised options to acquire 5,781 shares of Edgewise Therapeutics’ common stock at a price of $0. Additionally, Carruthers acquired 26,875 restricted stock units and options to buy 161,250 shares. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 28.87, indicating robust short-term financial health. For deeper insights into EWTX’s valuation and additional ProTips, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025, with a loss of $0.34 per share compared to analysts’ projections of a $0.42 loss. The company maintains a robust cash position of about $594 million as of June 30, 2025, which supports its ongoing clinical initiatives. Following these financial results, RBC Capital raised its price target for Edgewise Therapeutics to $49, maintaining an Outperform rating. Similarly, Raymond James reaffirmed its Strong Buy rating with a $46 price target, emphasizing the company’s progress and upcoming milestones. Both firms highlighted the EDG-7500 Phase 2 CIRRUS-HCM Part D results anticipated in the fourth quarter of 2025 as a key catalyst. Earlier trial data indicated positive efficacy signals, although there were concerns about atrial fibrillation in some patients. These developments underline the company’s steady advancement in its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.